GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Piotroski F-Score

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 2001. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Dr Reddy's Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Dr Reddy's Laboratories's Piotroski F-Score or its related term are showing as below:

RDY' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Dr Reddy's Laboratories was 9. The lowest was 4. And the median was 6.


Dr Reddy's Laboratories Piotroski F-Score Historical Data

The historical data trend for Dr Reddy's Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 6.00 5.00 6.00 8.00

Dr Reddy's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 7.00 7.00 7.00

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Reddy's Laboratories Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 116.597 + 170.568 + 178.163 + 165.626 = $631 Mil.
Cash Flow from Operations was 239.21 + 136.819 + 215.794 + 56.898 = $649 Mil.
Revenue was 765.415 + 819.505 + 828.241 + 866.601 = $3,280 Mil.
Gross Profit was 437.566 + 481.033 + 485.952 + 506.919 = $1,911 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(3750.282 + 3912.334 + 4074.675 + 4177.465 + 4478.367) / 5 = $4078.6246 Mil.
Total Assets at the begining of this year (Dec22) was $3,750 Mil.
Long-Term Debt & Capital Lease Obligation was $74 Mil.
Total Current Assets was $2,864 Mil.
Total Current Liabilities was $1,124 Mil.
Net Income was 11.485 + 152.081 + 138.66 + 151.212 = $453 Mil.

Revenue was 713.588 + 667.87 + 785.72 + 820.867 = $2,988 Mil.
Gross Profit was 377.256 + 333.026 + 464.115 + 486.13 = $1,661 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(3746.929 + 3843.399 + 3790.178 + 3625.673 + 3750.282) / 5 = $3751.2922 Mil.
Total Assets at the begining of last year (Dec21) was $3,747 Mil.
Long-Term Debt & Capital Lease Obligation was $18 Mil.
Total Current Assets was $2,358 Mil.
Total Current Liabilities was $1,023 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Dr Reddy's Laboratories's current Net Income (TTM) was 631. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Dr Reddy's Laboratories's current Cash Flow from Operations (TTM) was 649. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=630.954/3750.282
=0.16824175

ROA (Last Year)=Net Income/Total Assets (Dec21)
=453.438/3746.929
=0.1210159

Dr Reddy's Laboratories's return on assets of this year was 0.16824175. Dr Reddy's Laboratories's return on assets of last year was 0.1210159. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Dr Reddy's Laboratories's current Net Income (TTM) was 631. Dr Reddy's Laboratories's current Cash Flow from Operations (TTM) was 649. ==> 649 > 631 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=73.894/4078.6246
=0.01811738

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=17.666/3751.2922
=0.00470931

Dr Reddy's Laboratories's gearing of this year was 0.01811738. Dr Reddy's Laboratories's gearing of last year was 0.00470931. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=2864.451/1124.27
=2.54783193

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=2358.167/1023.149
=2.30481289

Dr Reddy's Laboratories's current ratio of this year was 2.54783193. Dr Reddy's Laboratories's current ratio of last year was 2.30481289. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Dr Reddy's Laboratories's number of shares in issue this year was 166.776. Dr Reddy's Laboratories's number of shares in issue last year was 166.391. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1911.47/3279.762
=0.58280753

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1660.527/2988.045
=0.55572356

Dr Reddy's Laboratories's gross margin of this year was 0.58280753. Dr Reddy's Laboratories's gross margin of last year was 0.55572356. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=3279.762/3750.282
=0.87453743

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=2988.045/3746.929
=0.79746507

Dr Reddy's Laboratories's asset turnover of this year was 0.87453743. Dr Reddy's Laboratories's asset turnover of last year was 0.79746507. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Dr Reddy's Laboratories has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Dr Reddy's Laboratories  (NYSE:RDY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Dr Reddy's Laboratories Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description

Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (Dr Reddy's Laboratories) Headlines

From GuruFocus